Gland Pharma signs global sterile injectables CDMO deal with $90–100 million annual revenue potential

The long-term manufacturing agreement covers 55 oncology and non-oncology products across three Gland Pharma sites, with commercial revenue expected to begin in 2029.

Gland Pharma has entered a strategic manufacturing and supply agreement with an undisclosed global pharmaceutical company covering technology transfer, development and commercial manufacturing of 55 sterile injectable products for global markets, with annualised revenue potential of approximately $90–100 million once fully commercialised.

The agreement significantly expands Gland Pharma’s CDMO portfolio and provides a long-term manufacturing programme spanning complex and conventional injectables across multiple delivery formats.

Field	Content
Alert Type	Deal
Companies	Gland Pharma; undisclosed global pharmaceutical company
Deal Type	Strategic manufacturing and supply agreement / CDMO partnership
Asset or Company	Portfolio of 55 sterile injectable SKUs
Therapy Area(s)	Oncology; multiple non-oncology therapy areas
Technology or Modality	Sterile injectable manufacturing, including vials, lyophilised products, ampoules and pre-filled syringes
Deal Value	Financial consideration was not disclosed. Gland Pharma estimates the programme could generate approximately $90–100 million in annualised revenue once the portfolio is fully commercialised; this is projected future revenue rather than a guaranteed transaction value. (The Economic Times)
Development Stage	Portfolio includes both commercially marketed products and pipeline products under development.
Geography	Global
What Happened	Gland Pharma announced on 9 August 2026 that it had entered a strategic Manufacturing and Supply Agreement with an undisclosed global pharmaceutical company covering 55 sterile injectable SKUs across three Gland Pharma manufacturing sites. Under the full-service CDMO arrangement, Gland Pharma will undertake technology transfer, process development, scale-up, validation, commercial manufacturing and long-term supply, alongside quality and regulatory support. Technology transfer is expected to be completed within two years, with revenue generation planned to begin in calendar year 2029. (The Economic Times)
Why It Matters	The agreement provides Gland Pharma with a sizeable long-term CDMO programme covering a diversified portfolio rather than an individual product, increasing utilisation of its sterile manufacturing infrastructure and providing potential future revenue visibility. It also broadens the company’s role from manufacturing towards an integrated development, technology-transfer and supply partner, although the projected $90–100 million annual revenue depends on successful technology transfer and portfolio commercialisation. (The Economic Times)
Supporting Context	The portfolio spans complex and conventional injectable formulations across oncology and non-oncology products. CDMO is already an important part of Gland Pharma’s business, accounting for approximately 46% of FY26 revenue and growing 28% year on year. (The Economic Times)

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com